← All indications
Otitis Media
Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.
Subtype terms (4)
More specific conditions that are subtypes of Otitis Media in the MeSH hierarchy.
- Mastoiditis
2 drugs approved
- Otitis Media, Suppurative
10 drugs (8 approved, 2 experimental)
- Otitis Media with Effusion
17 drugs (11 approved, 6 experimental)
- Petrositis
Drugs by status
Approved for this indication (22)
Phase 4 trials (13)
Phase 3 trials (27)
- levofloxacin
- chamomile
- diphenhydramine
- betamethasone
- echinacea
- exe844
- glycerin
- iodine
- platelet-rich plasma
- lidocaine
- telithromycin
- xylitol
- multi-valent pneumococcal conjugate vaccine
- dexmedetomidine
- pneumococcal 7-valent conjugate vaccine
- triamcinolone
- midazolam
- sanguinaria canadensis
- capsicum
- hydrargyrum bicyanatum
- hydrastis canadensis
- sodium tetraborate
- moxifloxacin
- aconitum
- hydrastine
- fluocinolone acetonide
- 15-valent pneumococcal conjugate vaccine
Phase 2 trials (9)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (22)
- Abbott
- Merck
- Genentech
- Hamilton Health Sciences Corporation
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Pittsburgh
- Albany Medical College
- Baylor University
- Boston University
- Harvard University
- McMaster University
- Menzies School of Health Research
- University of Melbourne
- University of Oslo
- University of Oulu
- University of British Columbia
- University of Colorado, Denver
- University of Turku
- Allegheny Health Network
- National Health and Medical Research Council, Australia
- Government of Finland
- Lumbini Medical College
Organization Involved with Phase 3 Indications (24)
- Daiichi Sankyo
- Arbor Pharmaceuticals
- Grunenthal
- Aventis
- Sanofi
- Sanofi-Aventis
- Wyeth
- Alcon
- GlaxoSmithKline
- Lachlan Pharma Holdings
- Otonomy, Inc.
- Par Pharmaceuticals
- Salvat
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- Hormozgan University of Medical Sciences
- Ohio State University
- Papua New Guinea Institute of Medical Research
- University of Sydney
- Mayo Clinic
- Novum Pharmaceutical Research Services
- Telethon Institute for Child Health Research
- University of Tuebingen
- University of Western Australia
- Johnson and Johnson
Organization Involved with Phase 2 Indications (13)
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (22)
- Recordati
- ProbiSearch SL
- National Center for Complementary and Integrative Health (NCCIH)
- University of Arizona
- Duke University
- Lund University
- Ochsner Health System
- Utrecht University
- Yonsei University
- Tel Aviv University
- Uppsala University
- University of Haifa
- Kathmandu University
- Emek Medical Center
- University of Ljubljana
- Technion University
- Wonju Christian Hospital
- Washington University in St. Louis
- Doris Duke Charitable Foundation
- Dutch Health Care Insurance Board
- University of Antwerp
- University of Helsinki